Jasper reports more data in spontaneous hives from tiny study

Max Gelman

Senior Editor

Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest results came from a small trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Jasper reports more data in spontaneous hives from tiny study

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Judge halts some NIH cuts after 22 states sue

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Jasper re­ports more da­ta in spon­ta­neous hives from tiny study

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Jasper reports more data in spontaneous hives from tiny study